ADMA BIOLOGICS, INC. (ADMA)
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical
FSK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that FS KKR Capital Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
IQM incorpora a Barbara Venneman, consejera de Vanguard y exresponsable global de Deloitte Digital, a su Consejo de Administración
Shareholder Alert: Ademi LLP Continues to Investigate Claims of Securities Fraud against Via Transportation, Inc
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against GPGI, Inc.
ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc.
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
ERAS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ResMed Inc. Daily Stock Update